4.1 Review

Report of a European Working Group on late presentation with HIV infection: recommendations and regional variation

期刊

ANTIVIRAL THERAPY
卷 15, 期 -, 页码 31-35

出版社

INT MEDICAL PRESS LTD
DOI: 10.3851/IMP1525

关键词

-

资金

  1. Bristol Myers Squibb
  2. Abbott Laboratories
  3. Boehringer-Ingelheim
  4. Gilead
  5. GlaxoSmithKline
  6. Johnson Johnson
  7. MSD
  8. Pfizer
  9. Roche
  10. Schering Plough
  11. Tibotec
  12. ViiV
  13. Vertex

向作者/读者索取更多资源

Here, we present recommendations relevant to the diagnosis and management of late presentation with HIV infection, divided for convenience into four topic areas: the definition and epidemiology of late presentation, the medical and societal consequences of late presentation, earlier testing for HIV infection and the management of late presentation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据